23andMe Holding Co. (NASDAQ:ME) Shares Sold by NewView Capital Partners I LLC

NewView Capital Partners I LLC trimmed its position in shares of 23andMe Holding Co. (NASDAQ:ME) by 95.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 972,785 shares of the company’s stock after selling 18,482,896 shares during the period. 23andMe makes up about 8.8% of NewView Capital Partners I LLC’s holdings, making the stock its 2nd biggest holding. NewView Capital Partners I LLC owned 3.72% of 23andMe worth $3,162,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in 23andMe in the 2nd quarter valued at $203,000. Geode Capital Management LLC increased its holdings in 23andMe by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in 23andMe in the 2nd quarter valued at $43,000. Vanguard Personalized Indexing Management LLC boosted its position in 23andMe by 410.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock valued at $35,000 after buying an additional 71,204 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in 23andMe in the 4th quarter valued at about $26,000. 36.10% of the stock is currently owned by institutional investors and hedge funds.

23andMe Price Performance

NASDAQ:ME opened at $3.41 on Thursday. The firm has a 50-day moving average of $3.57 and a two-hundred day moving average of $5.73. 23andMe Holding Co. has a 1-year low of $2.65 and a 1-year high of $16.52.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The firm had revenue of $44.07 million during the quarter, compared to analysts’ expectations of $50.30 million. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.